ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
The COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.
By applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
New, ongoing, free event series about researchers work in the exciting fields of multi-omics. Each session will take a particular field of omics research and showcase some of the exciting research being undertaken from around the world.
Easier access for central European companies to cryo-EM technique! A modern Thermo Scientific Glacios transmission electron microscope has just been installed at Synchrotron Solaris in Poland and it is open for industrial users.
This white paper focuses on a new generation of single-use bioreactors, built to deliver high-volume performance and how they address many issue.
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Gene Editing?CRISPR-Cas9 gene editing offers substantial improvements over previous gene editing technologies in terms of ease of use, speed, efficacy, and cost. Not surprisingly, CRISPR-Cas9 editing has taken biomedical science by storm. While the technology is relatively simple in handling at the level of basic research, the use of CRISPR genome editing in therapeutical applications poses a bunch of
analytical challenges.
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.